Generated by AI
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications. The company’s pipeline also includes ALX2004, an epidermal growth factor receptor-targeted antibody-drug conjugate under development for EGFR-expressing tumors. ALX Oncology’s work centers on protein engineering, combination therapy research, and clinical studies aimed at addressing difficult-to-treat cancers. Based in South San Francisco, California, the company operates within the broader oncology drug development market and collaborates with clinical trial sites and research partners to advance its product candidates.
Website323 Allerton Avenue
South San Francisco, CA, 94080
United States
The latest articles about ALXO.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences. The details of the meetings are as follows: UBS London Healthcare Conference Format: Fireside Chat and One-on-one MeetingsDate
Tipranks Press Release.
Tipranks Press Release.
Summary of Feb 27's posts. Generated by AI.
Summary of Aug 27's posts. Generated by AI.
Summary of Oct 4's posts. Generated by AI.
Investors talking about ALXO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.